Steven Leonard Chapman, CEO and President of Natera (NASDAQ:NTRA), sold 1,698 shares of common stock on Sept. 1, 2026, according to a recent SEC Form 4 filing. Transaction value based on SEC Form 4 weighted average sale price ($320.99); post-transaction value based on Sept. 1, 2026, market close ($320.76). What was the primary driver for this liquidation?The transaction was executed under a Rule 10b5-1 plan amended in March 2026, which allows corporate insiders to schedule share sales in advance to avoid concerns regarding material non-public information.
What is the executive's remaining ownership concentration in the firm?Following this transaction, Chapman maintains a direct ownership stake representing approximately 0.06% of the company's total equity. How has the stock performed relative to this transaction?The sale occurred for $320.99, while the stock has produced a 91% total return over the 12 months ending on the Sept. 1, 2026, transaction date. Does the insider hold exposure beyond common equity?In addition to the 98,199 shares held directly, Chapman holds derivative securities that provide continued economic interest in the company's performance.
Share Price (as of market close 2026-09-02) Natera develops and commercializes a comprehensive portfolio of molecular diagnostic tests, including Panorama for non-invasive prenatal testing, Vistara for single-gene disorder screening, and Horizon for carrier screening, generating revenue through test volume and clinical adoption globally. The company operates a diagnostics-as-a-service business model, leveraging proprietary molecular testing technology to deliver clinical insights to healthcare providers and patients, with revenue derived from per-test fees and volume-based contracts with healthcare systems. Natera's primary customers include obstetric and gynecology practices, reproductive endocrinology clinics, and healthcare systems, with target markets spanning prenatal screening, carrier screening, and single-gene disorder detection across developed healthcare markets.
Natera is a leading molecular diagnostics company with a market capitalization of $52.1 billion and TTM revenue of $2.7 billion, positioning it as a significant player in the reproductive and genetic testing market. The company's competitive advantage derives from its proprietary testing platforms, extensive clinical validation, and established relationships with healthcare providers across multiple geographies. Despite current net losses of $192.3 million TTM, Natera demonstrates strong revenue growth and market momentum, reflecting investor confidence in its diagnostic solutions and market expansion potential.
On Sept. 1, Chapman sold nearly 1,700 shares on Sept. 1, 2026. Looking into the transaction details, this is just a routine sale that shouldn't worry shareholders. The main reason is that this sale was already part of a preplanned trade adopted in December 2023 and amended in March 2026.
That means that, in and of itself, this sale wasn't indicative of anything being amiss at Natera. Rather, it was just an insider selling shares under an established trading plan, so it wasn't a knee-jerk reaction or a spur-of-the-moment decision. Overall, that means this isn't a sale to worry about.
Extract — continue reading at the source.
